Gene · 6607
Papers3,510
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
721 to 740 of 3,510
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Adherence and Persistence to Nusinersen for Spinal Muscular Atrophy: A US Claims-Based Analysis. | Adv Ther | 2023 | 36534265 | PubTator, text mining | PubMed |
| Patient Reported Outcome Measures in Adult Spinal Muscular Atrophy: A Scoping Review and Graphical Visualization of the Evidence. | J Neuromuscul Dis | 2023 | 36530090 | PubTator, text mining | PubMed |
| Human genetic diversity alters off-target outcomes of therapeutic gene editing. | Nat Genet | 2023 | 36522432 | PubTator, text mining | PubMed |
| Consensus Guidelines for the Design and In Vitro Preclinical Efficacy Testing N-of-1 Exon Skipping Antisense Oligonucleotides. | Nucleic Acid Ther | 2023 | 36516128 | PubTator, text mining | PubMed |
| Non-coding RNA regulation of integrins and their potential as therapeutic targets in cancer. | Cell Oncol (Dordr) | 2023 | 36512308 | PubTator, text mining | PubMed |
| A pediatric quantitative systems pharmacology model of neurofilament trafficking in spinal muscular atrophy treated with the antisense oligonucleotide nusinersen. | CPT Pharmacometrics Syst Pharmacol | 2023 | 36471456 | PubTator, text mining | PubMed |
| Newbornscreening SMA - From Pilot Project to Nationwide Screening in Germany. | J Neuromuscul Dis | 2023 | 36463459 | PubTator, text mining | PubMed |
| Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey. | Neurology | 2023 | 36460469 | PubTator, text mining | PubMed |
| Scaling genetic resources: New paradigms for diagnosis and treatment of rare genetic disease. | Am J Med Genet C Semin Med Genet | 2023 | 36448938 | PubTator, text mining | PubMed |
| Polysomnography findings in children with spinal muscular atrophy after onasemnogene-abeparvovec. | Sleep Med | 2023 | 36442421 | PubTator, text mining | PubMed |
| Population WGS-based spinal muscular atrophy carrier screening in a cohort of 1076 healthy Polish individuals. | J Appl Genet | 2023 | 36417168 | PubTator, text mining | PubMed |
| Experience of a 2-year spinal muscular atrophy NBS pilot study in Italy: towards specific guidelines and standard operating procedures for the molecular diagnosis. | J Med Genet | 2023 | 36414255 | PubTator, text mining | PubMed |
| RNA-based drug discovery for spinal muscular atrophy: a story of small molecules and antisense oligonucleotides. | Expert Opin Drug Discov | 2023 | 36408582 | PubTator, text mining | PubMed |
| Significant healthcare burden and life cost of spinal muscular atrophy: real-world data. | Eur J Health Econ | 2023 | 36403177 | PubTator, text mining | PubMed |
| SMA-linked SMN mutants prevent phase separation properties and SMN interactions with FMRP family members. | Life Sci Alliance | 2023 | 36375840 | PubTator, text mining | PubMed |
| Risk factors for recurrent respiratory tract infections and acute respiratory failure in children with spinal muscular atrophy. | Pediatr Pulmonol | 2023 | 36367332 | PubTator, text mining | PubMed |
| New treatments in spinal muscular atrophy. | Arch Dis Child | 2023 | 36316089 | PubTator, text mining | PubMed |
| Disease Burden of Spinal Muscular Atrophy: A Comparative Cohort Study Using Insurance Claims Data in the USA. | J Neuromuscul Dis | 2023 | 36314213 | PubTator, text mining | PubMed |
| CSF IL-8 Associated with Response to Gene Therapy in a Case Series of Spinal Muscular Atrophy. | Neurotherapeutics | 2023 | 36289175 | PubTator, text mining | PubMed |
| A splicing silencer in SMN2 intron 6 is critical in spinal muscular atrophy. | Hum Mol Genet | 2023 | 36255739 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6607/papers?page=37